Haemonetics

HAE

Market cap $3.47B

Haemonetics Corporation (HAE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

$11 million in proceeds expected to be received during 2026, with remainder of expected proceeds to be received in future revenue earnouts Vivasure Medical Limited (“Vivasure”) has been a strategic holding of Orchestra BioMed since the Company's formation NEW HOPE, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that it expects to receive up to $21 million in cash proceeds in connection with the acquisition of Vivasure, an Ireland-based company pioneering next-generation technology for percutaneous vessel closure, by Haemonetics Corporation (NYSE: HAE, “Haemonetics”), which closed on January 9, 2026.

Haemonetics (HAE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced that the company has been acquired by Haemonetics Corporation (NYSE: HAE) in a transaction valued up to €185M (~$215M) on completion of certain milestones. Based in Galway, Ireland, Vivasure is focused on the development of advanced polymer implants and delivery systems, primarily focused on minimally invasive vessel closure in cardiology,.

BOSTON, Jan. 9, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced the acquisition of Vivasure Medical Limited (Vivasure), a Galway, Ireland-based company pioneering next-generation technology for percutaneous vessel closure. Vivasure's PerQseal® Elite system uses a proprietary bioabsorbable patch to seal large-bore (up to 26 F) arteriotomies and venotomies from inside the vessel, offering a sutureless, fully absorbable solution for structural heart and endovascular procedures.

BOSTON, Jan. 7, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, February 5, 2026. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on February 5, 2026.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

BOSTON, Jan. 2, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 7:30 am Pacific Time.

Currently priced at approximately $80.53 per share, Haemonetics (NYSE: HAE) is trading roughly 7.6% below its 52-week high.